Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer
Katrin Frenzel(Uppsala University Hospital), Uğur Şahin(Johannes Gutenberg University Mainz), Sebastian Kreiter(Johannes Gutenberg University Mainz), Tobias Sjöblom(Uppsala University), Klaus Kuehlcke, Stefanie Bolte(BioNTech (Germany)), Ludwig Heesen(Uppsala University Hospital), Marcus Schmidt(Johannes Gutenberg University Mainz), Evelyna Derhovanessian(University of Tübingen), Henrik Lindman(Uppsala University), Laurence Zitvogel(Institut Gustave Roussy), Valesca Bukur(Uppsala University Hospital), Mustafa Diken, Jacques De Grève(Vrije Universiteit Brussel), Steve Pascolo(University of Zurich), Andreas Schneeweiß(German Cancer Research Center), Martin Löwer, Özlem Türeci(Johannes Gutenberg University Mainz), K Thielemans, Andreas N. Kuhn(Uppsala University Hospital)
Cited by 2
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k